Search results

Filter (8 in use)

Type 1 selected

Status 2 selected

Last updated 1 selected

Guidance programme 4 selected

65 results

Relevance Date

  1. Givosiran for treating acute hepatic porphyria (HST16)

    Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over

    Highly specialised technologies guidance
    Published
    View recommendations

  2. Odevixibat for treating progressive familial intrahepatic cholestasis (HST17)

    Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

    Highly specialised technologies guidance
    Published
    View recommendations

  3. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

    Highly specialised technologies guidance
    Published
    View recommendations

  5. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

    Highly specialised technologies guidance
    Published
    View recommendations

  6. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules

    Diagnostics guidance
    Published
    View recommendations

  7. PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)

    Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease

    Diagnostics guidance
    Published
    View recommendations

  9. Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)

    Evidence-based recommendations on endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. This involves removing a tumour using an endoscope and forceps. The aim is to remove the tumour without the need for open surgery

    Interventional procedures guidance
    Published
    View recommendations

  10. Endoscopic balloon dilation for subglottic or tracheal stenosis (IPG719)

    Evidence-based recommendations on endoscopic balloon dilation for subglottic or tracheal stenosis. This involves introducing a balloon device with the aim of widening the stenotic airway to improve symptoms

    Interventional procedures guidance
    Published
    View recommendations

  11. Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (IPG711)

    Evidence-based recommendations on percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure in adults

    Interventional procedures guidance
    Published
    View recommendations

  12. Stereotactic radiosurgery for trigeminal neuralgia (IPG715)

    Evidence-based recommendations on stereotactic radiosurgery for trigeminal neuralgia in adults. This involves focussing radiation on the trigeminal nerve to damage it, thereby relieving pain

    Interventional procedures guidance
    Published
    View recommendations

  13. Intramedullary distraction for lower limb lengthening (IPG718)

    Evidence-based recommendations on intramedullary distraction for lower limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter leg

    Interventional procedures guidance
    Published
    View recommendations

  15. Intramedullary distraction for upper limb lengthening (IPG722)

    Evidence-based recommendations on intramedullary distraction for upper limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter arm

    Interventional procedures guidance
    Published
    View recommendations

  17. Coronary sinus narrowing device implantation for refractory angina (IPG712)

    Evidence-based recommendations on coronary sinus narrowing device implantation for refractory angina in adults. This involves putting a device into the coronary sinus to narrow it with the aim of improving the flow of oxygenated blood throughout the heart muscle

    Interventional procedures guidance
    Published
    View recommendations

  19. Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)

    Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing

    Interventional procedures guidance
    Published
    View recommendations

  20. Microwave ablation for primary or metastatic cancer in the lung (IPG716)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation)

    Interventional procedures guidance
    Published
    View recommendations

  21. Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis (IPG720)

    Evidence-based recommendations on percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. This involves inserting a tube called a stent into or across the cystic duct. The aim is to allow bile to flow through the tube, bypassing the blockage and preventing further obstruction

    Interventional procedures guidance
    Published
    View recommendations

  22. Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome (IPG724)

    Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome

    Interventional procedures guidance
    Published
    View recommendations

  23. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus

    Technology appraisal guidance
    Published
    View recommendations

  24. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug

    Technology appraisal guidance
    Published
    View recommendations

  25. Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

    Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in

    Technology appraisal guidance
    Published
    View recommendations

  26. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults

    Technology appraisal guidance
    Published
    View recommendations

  27. Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

    Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults

    Technology appraisal guidance
    Published
    View recommendations

  28. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years an

    Technology appraisal guidance
    Published
    View recommendations

  29. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies

    Technology appraisal guidance
    Published
    View recommendations

  30. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of EGFR mutation positive non small cell lung cancer in adults after complete

    Technology appraisal guidance
    Published
    View recommendations

  35. Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

    Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults

    Technology appraisal guidance
    Published
    View recommendations

  38. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults

    Technology appraisal guidance
    Published
    View recommendations

  40. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable

    Technology appraisal guidance
    Published
    View recommendations

  41. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

    Technology appraisal guidance
    Published
    View recommendations

  43. Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

    Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders

    Technology appraisal guidance
    Published
    View recommendations

  46. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer

    Technology appraisal guidance
    Published
    View recommendations

  47. Cabotegravir with rilpivirine for treating HIV-1 (TA757)

    Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological

    Technology appraisal guidance
    Published
    View recommendations

  48. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

    Technology appraisal guidance
    Published
    View recommendations

  49. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

    Evidence-based recommendations on pegcetacoplan (Aspaveli) for treating paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor

    Technology appraisal guidance
    Published
    View recommendations